MABVAX THERAPEUTICS HOLDINGS, INC.
DelistedCIK 1109196fmd_0Q6PHHBFQSMP6745DD1KMEN364Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2018, 35 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 1 | 0 | 0 | 1 | 0 | 0 |
| Research and development | 13 | 11 | 6 | 3 | 3 | 4 | 10 | 8 | 8 |
| Total operating expenses | 24 | 26 | 12 | 4 | 4 | 9 | 19 | 17 | 18 |
| Operating income | (24) | (26) | (12) | (3) | (4) | (8) | (18) | (17) | (18) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | – | – | 1 | 1 |
| Interest and investment income | – | – | – | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | – | (0) | (0) | (0) | (0) | (1) | (1) |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income | (24) | (25) | (12) | (3) | (4) | (8) | (18) | (18) | (19) |
| Net income to common shareholders | – | – | – | (3) | (5) | (11) | (36) | (18) | (33) |